Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MGN 1601

Next Previous
Drug Profile

MGN 1601

Alternative Names: MGN-1601

Latest Information Update: 24 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mologen
  • Class Cancer vaccines; Cell therapies; Gene therapies; Tumour cell vaccines
  • Mechanism of Action Cell replacements; Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Renal cancer

Most Recent Events

  • 09 Jun 2016 Suspended - Phase-I/II for Renal cancer (Late-stage disease) in Germany (Intradermal)
  • 16 Sep 2015 Phase-I/II development is ongoing for Renal cancer in Germany
  • 07 May 2014 Further efficacy data from a phase I/II trial in Renal cancer released by Mologen

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top